CLINICAL TRIAL

Beyond the Self and Back: Neuropharmacological Mechanisms Underlying the Dissolution of the Self

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2020-11-04
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University of Zurich

Watch author

Derived topics and classifications

psilocybin Brain Imaging Mechanism of Action Aging Mystical Experience Healthy Volunteers Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Characterization of Altered Waking States of Consciousness in Healthy HumansClinicalTrials.gov · 2021-04-29 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09 A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy VolunteersClinicalTrials.gov · 2026-02-13 Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced MeditatorsClinicalTrials.gov · 2023-09-21 Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14 Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyClinicalTrials.gov · 2026-08-07 Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-23 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21